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Anti-endotoxin therapy and the management of
More than 20 years ago, it was postulated that
antibodies directed against the core region of
lipopolysaccharide (LPS) could recognize an
epitope shared by endotoxins from pathogenic
Gram-negative bacteria. Although this postu-
lated common epitope could not be precisely
characterized, lipid A has been considered as
an attractive candidate since it is the most
conserved component of LPS and is the toxic
part of the molecule. These researches culmi-
nated recently in clinical studies performed
with two monoclonal antibodies (mAbs),
called E5 and HA 1-1A (Centoxin), directed at
lipid A. One of the mAb, HA1-1A, has been
licensed in some European countries. The cost
of the antibody is high and the financial
impact of such treatment is likely to be con-
siderable; this is likely to cause budgetary
problems (Taylor, 1991), leading to competi-
tion for increasingly scarce medical resources.
The real impact that such therapy will have on
the outcome of septic patients should therefore
be carefully studied, and those who might
benefit should be carefully defined. Previous
data in this field, together with a detailed
analysis of the clinical studies using the two
mAbs should provide guidance.
Despite modern technology, many questions
remain unanswered concerning the character-
ization and the biological effects of polyclonal
or monoclonal anti-core LPS antibodies. The
pattern of in-vitro reactivity of these anti-
bodies with LPS from pathogenic bacteria has
not been clarified. The reactivity in ELISA
tests deserves confirmation by other methods,
since LPS are amphophilic substances which
form aggregates, bind poorly to ELISA plates
and promote non-specific sticking of immuno-
globulins to LPS hydrophobic regions
(Freudenberg et al., 1989; Heumann et al.,
1991). Even with mAbs, opposite interpreta-
tions of in-vitro results have sometimes been
published. For instance, whereas HA-1A was
reported to specifically recognize lipid A and
to have a broad cross-reactivity in ELISA
(ZiegleT et al., 1991), some observations have
suggested that its binding to lipid A might be
the result of non-specific interactions with
hydrophobic substances (Baumgartner, 1991).
Recently, detailed studies of several
anti-lipid A mAbs have revealed a lack of
cross-reactivity with LPS, i.e. the attachment
of the inner core to lipid A seemed to prevent
the binding of anti-lipid A antibodies to the
lipid A component of LPS (Iind, Kenne &
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Table. Clinical studies with human JS antiserum, immune plasma or anti-core LPS intravenous immune
globulins (IVIG)
Type of preparation
(reference)
Therapeutic studies
JS antiserum
(Ziegler et al., 1982)
JS plasma (Girardin et al,
1992)
Anti-£. colt J5 IVIG
(Calandra et al., 1988)
Prophylactic studies
JS antiserum (McCutchan
et al., 1983)
JS plasma (Baumgartner
et al., 1985)
Anti-Re LPS IVIG
(A. Cometta et al..
unpublished)
Study population
suspected Gram-negative
bacteraemia and/or shock
fuhninant TT1 T^1"1grKTMTal
purpura
Gram-negative septic shock
neutropenic cancer patients A
bone marrow transplant
recipients
high-risk post-surgical patients
high-risk post-surgical patients
No. of
patients
304
73
100
100
268
•
352
Outcome
reduction in mortality
no apparent benefit
no benefit
failure to prevent fever and
Gram-negative sepsis
failure to prevent
Gram-negative infection;
prevention of shock and death
due to Gram-negative
infections of borderline
significance*
no benefit
"Statistically significant only with one-tailed Fisher's tests: the P values obtained with the Chi-tquare test
were 0-10 for the difference in the incidence of Gram-negative shock between JS plasma (15/136 patients)
and normal plasma (6/126) recipients, and 0-08 for the associated mortality (9/136 and 2/126, respectively).
Lindberg, 1991; Rietschel et al., 1991).
Another area of concerns is the existence of
important discrepancies in experiments of
cross-protection. Differences in the animal
models used cannot explain all the discrepan-
cies, since opposite results have sometimes
been obtained using similar models and similar
bacterial or LPS challenges. For instance,
HA-1A was reported to protect experimentally
challenged mice and rabbits when tested as a
crude hybridoma fluid (Teng et al., 1985).
Using a highly purified form of this antibody,
there results could not be reproduced (Baum-
gartner et al., 1990). Finally, the inconsistent
results in clinical studies using various poly-
clonal antibodies is puzzling (Table).
Whole human serum or plasma from volun-
teers after immunization with boiled E. coll JS
cells has been studied in the treatment of
Gram-negative bacteraemia (Ziegler et al.,
1982) and fulminant meningococcacinia
(Girardin et al., 1992), and in the prophylaxis
of Gram-negative systemic infections in neu-
tropenic patients (McCutchan et al., 1983) and
in high risk post-surgical patients (Baum-
gartner et al., 1985). Hyperimmune anti-core
LPS intravenous globulin has been studied in
the treatment of Gram-negative septic shock
(Calandra et al., 1988) and in the prophylaxis
of Gram-negative systemic infections in high
risk surgical patients (A. Cometta et al.,
unpublished). Only two of these six studies
appeared successful (Ziegler et al., 1982;
Baumgartner et al., 1985). However, the mech-
anism of protection in these two studies with
J5 antiserum remaines unknown, but is not
attributable to anti-lipid A antibodies since the
levels of these antibodies were similar in J5
antisenrm and control serum (Baumgartner et
al., 1991). Since the mechanism of protection
remains obscure, it is difficult to explain why
some clinical studies have given positive results
and others have not.
In the study of the E5 mAb (Greenman et
al., 1991), 486 patients with a septic syndrome
believed to result from Gram-negative infec-
tion, were randomly assigned to receive this
antibody or an identical volume of saline. No
decrease in mortality was observed in the over-
all group of 468 assessable patients nor in the
316 patients who subsequently proved to
have a documented Gram-negative infection.
Among these 316 patients, there was a statisti-
cally significant decrease in mortality in 137
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patients without shock at trial entry (P — 003,
Kaplan-Meier), but 179 patients with shock
were not protected. A second multicentre
study of 931 patients, specifically designed to
verify these results, failed to confirm that E5
was able to improve the survival of patients
with Gram-negative septic syndromes without
shock (Wcnzel et al., 1991).
The second antibody, HA-1A, was studied
in 607 patients with a presumptive diagnosis of
Gram-negative sepsis, among whom 543 were
evaluated (Ziegler et al., 1991). Among the 401
patients with Gram-negative infections, the
sepsis syndrome was definitely attributed to
Gram-negative bacteria if blood cultures
were positive for a Gram-negative bacteria
(200 patients), probably if negative blood cul-
tures were felt to be due to the presence of
antibacterial agents (117 patients), and poss-
ibly if blood cultures were negative despite the
absence of an effective antibacterial agent
(84 patients). HA-1A did not reduce the
mortality at 28 days in the overall study popu-
lation (43% in the placebo recipients and 39%
in the HA-1A recipients), nor did it reduce
mortality in the 142 patients without
documented Gram-negative infections.
Furthermore it failed to reduce mortality, even
marginally, in the 401 patients with
Gram-negative infections, as well as the 117
patients with probable Gram-negative sepsis,
and the 84 patients with possible
Gram-negative sepsis. However, there was a
decrease in mortality in the 200 patients with
Gram-negative bacteraemia (49% (mAb) and
30% (placebo), respectively, P = 0014). The
difference was more significant among the 101
patients who were in shock than among the 99
patients not in shock.
These data reveal that the selection of the
patients who might benefit from this treatment
will present a major problem. The mortality
rate was identical in HA-1A and placebo reci-
pients among all patients treated and in
patients with non-bacteraemic Gram-negative
sepsis syndromes. The clinical trial of HA-1A
was designed to select as precisely as possible
patients with a septic syndrome due to
Gram-negative infections. At present there is
no rapid diagnostic test which allows more
precise selection of the subset of patients pre-
senting with Gram-negative bacteraemia. To
await the results of blood culture does not
seem realistic. Since HA-1A costs £2200 (plus
Value Added Tax) per single dose, some medi-
cal economists have indicated that the cost of
this treatment, if widely adopted, could absorb
almost 20% of the current expenditure on
drugs by NHS hospitals in the United
Kingdom (Taylor, 1991).
Detailed analysis of the study reveals
• another cause for concern. There may have
been imbalances in risk factors at randomiza-
tion between placebo and HA-1A recipients
in the subgroup of 200 patients with
Gram-negative bacteraemia (Carlet et al.,
1991); in table 4 of the published study (Ziegler
et al., 1991), it can be calculated that a total of
101 serious complications (disseminated intra-
vascular coagulation, adult respiratory distress
syndrome, acute hepatic failure and acute
renal failure) were observed at entry among
the 95 placebo recipients (a mean of 1-06 per
patient) compared to 85 among the 105
HA-1A recipients (0-81 per patient). Although
a Cox proportional-hazards model revealed
that the difference remained significant among
both severely ill (APACHE II score > 25) and
less severely ill patients (APACHE II score
< 25) (Ziegler et al., 1991), these 16 additional
serious complications in the placebo group
might nevertheless account for some of the
higher mortality in this group of patients (13
excess deaths).
Since our basic understanding of the speci-
ficity and of the function of HA-1A is incom-
plete; since animal protection studies have
given discrepant results; since other clinical
studies with similar anti-LPS antibodies have
failed to show benefit, the possible imbalance
between the test and controlled groups at entry
in the HA-1A study suggests that it may be
premature to rely on the single clinical HA-1A
study before widely adopting this novel thera-
peutic approach to sepsis. Despite the present
urgent need for adjunctive therapy of
Gram-negative septic shock, the use of anti-
bodies directed at lipid A or at other epitopes
of the core LPS should still be considered
investigational. Clearly, further basic research
is needed to clarify the protective mechanism
of such antibodies in advance of further
clinical trials.
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